0001209191-23-024386.txt : 20230414 0001209191-23-024386.hdr.sgml : 20230414 20230414191722 ACCESSION NUMBER: 0001209191-23-024386 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230412 FILED AS OF DATE: 20230414 DATE AS OF CHANGE: 20230414 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Donegan Michael C CENTRAL INDEX KEY: 0001627810 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-00100 FILM NUMBER: 23822521 MAIL ADDRESS: STREET 1: 6800 BROKEN SOUND PARKWAY NW STREET 2: THIRD FLOOR CITY: BOCA RATON STATE: FL ZIP: 33487-3507 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TherapeuticsMD, Inc. CENTRAL INDEX KEY: 0000025743 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870233535 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 951 YAMATO ROAD, SUITE 220 CITY: BOCA RATON STATE: FL ZIP: 33431 BUSINESS PHONE: 561-961-1900 MAIL ADDRESS: STREET 1: 951 YAMATO ROAD, SUITE 220 CITY: BOCA RATON STATE: FL ZIP: 33431 FORMER COMPANY: FORMER CONFORMED NAME: AMHN, Inc. DATE OF NAME CHANGE: 20090930 FORMER COMPANY: FORMER CONFORMED NAME: CROFF ENTERPRISES INC DATE OF NAME CHANGE: 19970915 FORMER COMPANY: FORMER CONFORMED NAME: CROFF OIL CO DATE OF NAME CHANGE: 19920703 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-04-12 0 0000025743 TherapeuticsMD, Inc. TXMD 0001627810 Donegan Michael C 951 YAMATO ROAD SUITE 220 BOCA RATON FL 33431 0 1 0 0 Prin. Fin. and Acctg. Officer 0 Common Stock 2023-04-12 4 M 0 50000 0.00 A 61853 D Restricted Stock Units 0.00 2023-04-12 4 M 0 50000 0.00 D Common Stock 50000 0 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On April 12, 2023, the reporting person received 50,000 shares of issuer common stock in settlement of restricted stock units (RSUs). Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on March 31, 2023. /s/ Michael C. Donegan 2023-04-14